Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1).

James A Simon,Richard A Anderson,Elizabeth Ballantyne,James Bolognese,Cecilia Caetano,Hadine Joffe,Mary Kerr,Nick Panay,Christian Seitz,Susan Seymore,Mike Trower,Lineke Zuurman,Steve Pawsey

Menopause (New York, N.Y.)（2023）

引用 7|浏览23

暂无评分

摘要

Elinzanetant is an effective and well-tolerated nonhormone treatment option for postmenopausal women with VMS and associated sleep disturbance. Elinzanetant also improves quality of life in women with VMS.

查看译文

关键词

KNDy neuron,Menopause,Neurokinin B,Neurokinin-1,3 receptor antagonist,Substance P,Vasomotor symptoms

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要